The health technology assessment (HTA) landscape is evolving, as evidenced by a new collaborative initiative. HTA bodies from the United States, Canada, and England are uniting to explore how unconventional treatment benefits can be integrated into the appraisal process. The goal is to enhance the understanding of a product’s overall value, moving beyond traditional metrics.
This cross-Atlantic alliance, known as HEMA, is focused on incorporating benefits like “the value of hope” and “scientific spillover” into their assessments. These novel concepts represent a shift toward a more holistic approach to evaluating the worth of new medical interventions.
The collaboration’s initial guidance aims to assist HTAs in analyzing the full value of drugs, with a focus on these less-quantifiable aspects.
The first guidance from the HEMA HTA collaboration will assist HTAs in analyzing the value of drugs by considering novel treatment benefits.
